rivastigmine has been researched along with Disease Models, Animal in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (14.71) | 29.6817 |
| 2010's | 19 (55.88) | 24.3611 |
| 2020's | 10 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Decker, M; Endres, E; Gunesch, S; Hoffmann, M; Maurice, T; Scheiner, M; Sotriffer, C; Stiller, C | 1 |
| Bai, P; Chen, Z; Lan, Y; Liu, W; Qiao, Z; Sang, Z; Shi, J; Tan, Z; Wang, C; Wang, K; Wang, Y; Wu, A; Zhao, Y; Zhu, G | 1 |
| Hoe, HS; Jeong, HR; Kim, J; Lee, H; Lee, HJ; Lee, S; Park, JH; Park, SK; Seol, E | 1 |
| Cucos, CA; Dobre, M; Dragnea, EM; Manda, G; Milanesi, E | 1 |
| Akash, MSH; Akbar, M; Chaudhary, Z; Panichayupakaranant, P; Rehman, K; Shabbir, A; Shah, MA | 1 |
| Aameri, R; Ghorbani, H; Korani, B; Reza Bazrafshan, H; Zahra Gharib, F | 1 |
| Andrzejewski, K; Conde, SV; Jampolska, M; Kaczyńska, K; Mojzych, I | 1 |
| Mehrabadi, S; Moradbeygi, K; Motevaseli, E; Sadr, SS | 1 |
| Cranston, A; Harrington, CR; Klein, J; Kondak, C; Lauer, D; Magbagbeolu, M; Melis, V; Niewiadomska, G; Riedel, G; Santos, RX; Schwab, K; Steczkowska, M; Theuring, F; Wischik, CM; Wydrych, M; Zadrozny, M | 1 |
| Arumugam, K; Bojja, SL; Kumar, N; Rao, CM; Rompicherla, SKL | 1 |
| Castro-E-Silva, O; Chies, AB; D'Albuquerque, LAC; Gomes, MCJ; Nakazato, PCG; Spadella, MA; Zorzi, P | 1 |
| de Jong, IEM; Koshy Cherian, A; Kucinski, A; Sarter, M; Wu, R | 1 |
| Borah, A; Dutta, A; Gothwal, A; Gupta, U; Jain, SK; Singh, H | 1 |
| Nadler-Milbauer, M; Shifrin, H; Shoham, S; Weinstock, M | 1 |
| Fukunaga, K; Moriguchi, S; Narahashi, T; Sakagami, H; Sasaki, Y; Tagashira, H; Yeh, JZ | 1 |
| Gruca, P; Lason-Tyburkiewicz, M; Papp, M; Willner, P | 1 |
| Kaddoumi, A; Keller, JN; Mohamed, LA | 1 |
| Matsuda, T | 1 |
| Filarowska, J; Gawel, K; Gibula-Bruzda, E; Jenda, M; Kotlinska, JH; Labuz, K; Marszalek-Grabska, M; Silberring, J | 1 |
| Dziedzic, M; Gawel, K; Gibula-Bruzda, E; Jenda-Wojtanowska, M; Kotlinska, JH; Marszalek-Grabska, M; Silberring, J | 1 |
| Hisatsune, T; Matsuda, T | 1 |
| Wightman, EL | 1 |
| Candela, A; Cauli, O; Compañ, A; Felipo, V; García-Ayllón, MS; Jover, R; Martínez, S; Pérez-Mateo, M; Rodrigo, R; Sáez-Valero, J; Silveyra, MX | 1 |
| Tang, XC; Wang, J; Zhang, HY | 1 |
| Chavhan, SS; Joshi, SA; Sawant, KK | 1 |
| Dietrich, H; Grau, V; Hecker, A; Körner, C; Kummer, W; Padberg, W; Pfeil, U; Wessler, I; Wilczynska, J; Zakrzewicz, A | 1 |
| Alkam, T; Furukawa-Hibi, Y; Greig, NH; Matsuyama, A; Mizoguchi, H; Moussaoui, S; Nagai, T; Nitta, A; Suzuki, K; Yamada, K; Yu, QS | 1 |
| Brown, ME; Fahnestock, M; Francis, BM; Hajderi, E; McLaurin, J; Michalski, B; Mount, HT; Yang, J | 1 |
| Hassan, H; Hussein, A; Mahdy, K; Nassar, Y; Shaker, O; Wafay, H | 1 |
| Elmeshad, AN; Ismail, MF; Salem, NA | 1 |
| Ballmaier, M; Casamenti, F; Mazzoncini, R; Pepeu, G; Scali, C; Spano, PF; Zoli, M | 1 |
| Abramowski, D; De Deyn, PP; Staufenbiel, M; Van Dam, D | 1 |
| Fisher, A | 1 |
4 review(s) available for rivastigmine and Disease Models, Animal
| Article | Year |
|---|---|
Psychopharmacological Studies in Mice.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Dopamine; Drug Discovery; Environment; Female; Galantamine; Indans; Male; Mental Disorders; Mice; Molecular Targeted Therapy; Motivation; Piperidines; Psychopharmacology; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1D; Receptors, Dopamine D2; Research; Rivastigmine | 2016 |
Potential benefits of phytochemicals against Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Ginkgo biloba; Humans; Melissa; Panax; Phytochemicals; Plant Extracts; Resveratrol; Rivastigmine; Salvia officinalis; Stilbenes; Terpenes | 2017 |
Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.
Topics: Acetylcholine; Alkaloids; Animals; Anti-Inflammatory Agents; Cholinergic Agents; Cholinesterase Inhibitors; Dementia, Vascular; Disease Models, Animal; Donepezil; Galantamine; Humans; Indans; Inflammation; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, Cholinergic; Rivastigmine; Sesquiterpenes; Signal Transduction | 2009 |
Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Carbamates; Cheirogaleidae; Disease Models, Animal; Humans; Muscarinic Agonists; Neuroprotective Agents; Phenylcarbamates; Piperidines; Receptor, Muscarinic M1; Receptors, Muscarinic; Rivastigmine; Signal Transduction; tau Proteins; Thiazoles | 2000 |
30 other study(ies) available for rivastigmine and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Disease Models, Animal; Mice; Neuroprotective Agents | 2019 |
Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Cell Line; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Mice; Mice, Inbred Strains; Microsomes, Liver; Molecular Structure; Peptide Fragments; Positron Emission Tomography Computed Tomography; Protein Aggregates; Rats; Structure-Activity Relationship; Zebrafish | 2020 |
Donepezil Regulates LPS and Aβ-Stimulated Neuroinflammation through MAPK/NLRP3 Inflammasome/STAT3 Signaling.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Cells, Cultured; Cholinesterase Inhibitors; Cytokines; Disease Models, Animal; Donepezil; Inflammasomes; Inflammation; Lipopolysaccharides; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Mitogen-Activated Protein Kinases; NLR Family, Pyrin Domain-Containing 3 Protein; Rivastigmine; STAT3 Transcription Factor | 2021 |
Increased MYD88 blood transcript in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Disease Progression; Humans; Inflammation; Mice; Mice, Transgenic; Myeloid Differentiation Factor 88; Rivastigmine | 2022 |
Differential neuroprotective effect of curcuminoid formulations in aluminum chloride-induced Alzheimer's disease.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Biomarkers; Complex Mixtures; Diarylheptanoids; Disease Models, Animal; Humans; Interleukin-1alpha; Interleukin-1beta; Neuroprotective Agents; Rivastigmine; RNA, Messenger; Tumor Necrosis Factor-alpha | 2022 |
Iranian thyme honey plays behavioral, cellular and molecular important roles as an amazing preventive and therapeutic agent in the brain of Alzheimer's rat model.
Topics: Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Hippocampus; Honey; Humans; Iran; Maze Learning; Oxidative Stress; Rats; Rivastigmine; Thymus Plant | 2022 |
Hypoxic and Hypercapnic Responses in Transgenic Murine Model of Alzheimer's Disease Overexpressing Human AβPP: The Effects of Pretreatment with Memantine and Rivastigmine.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Disease Models, Animal; Humans; Hypercapnia; Hypoxia; Memantine; Mice; Mice, Transgenic; Quality of Life; Respiration; Rivastigmine | 2022 |
Hypoxic-conditioned medium from adipose tissue mesenchymal stem cells improved neuroinflammation through alternation of toll like receptor (TLR) 2 and TLR4 expression in model of Alzheimer's disease rats.
Topics: Adipose Tissue; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Culture Media, Conditioned; Disease Models, Animal; Hippocampus; Hypoxia; Inflammation; Interleukin-1beta; Learning; Male; Maze Learning; Mesenchymal Stem Cells; Peptide Fragments; Rats; Rats, Wistar; Recognition, Psychology; Rivastigmine; Spatial Memory; Toll-Like Receptor 2; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2020 |
Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Drug Interactions; Methylene Blue; Mice; Mice, Transgenic; Protein Aggregates; Rivastigmine; tau Proteins | 2020 |
Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Area Under Curve; Biological Availability; Cholinesterase Inhibitors; Colchicine; Disease Models, Animal; Liposomes; Male; Maze Learning; Memory Disorders; Models, Biological; Nanoparticles; Rats; Rats, Wistar; Rivastigmine; Scopolamine | 2021 |
Rivastigmine prevents injury induced by ischemia and reperfusion in rat liver.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Disease Models, Animal; Ischemia; Liver; Male; Mitochondria, Liver; Mitochondrial Myopathies; Rats; Rats, Wistar; Reperfusion Injury; Rivastigmine | 2018 |
Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease.
Topics: Accidental Falls; Animals; Basal Forebrain; Benzylamines; Cholinesterase Inhibitors; Cognitive Dysfunction; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Female; Indoles; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rivastigmine; Serotonin Antagonists | 2019 |
Behavioral and Biochemical Implications of Dendrimeric Rivastigmine in Memory-Deficit and Alzheimer's Induced Rodents.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Brain; Bridged-Ring Compounds; Disease Models, Animal; Drug Combinations; Maze Learning; Memory Disorders; Mice; Motor Skills; Organometallic Compounds; Polysaccharides; Rats; Rats, Wistar; Rivastigmine; Rotarod Performance Test; Scopolamine; Spatial Memory | 2019 |
Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses.
Topics: Animals; Anti-Inflammatory Agents; Brain; CD11b Antigen; Cell Line; Cholinesterases; Colitis, Ulcerative; Colon; Crohn Disease; Dextran Sulfate; Dinitrofluorobenzene; Disease Models, Animal; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Nitric Oxide; Peroxidase; Phenylcarbamates; Rats; Rivastigmine; Thiobarbituric Acid Reactive Substances; Tumor Necrosis Factor-alpha | 2013 |
CaMKII activity is essential for improvement of memory-related behaviors by chronic rivastigmine treatment.
Topics: Alzheimer Disease; Animals; Animals, Outbred Strains; CA1 Region, Hippocampal; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinase Type 4; Cholinesterase Inhibitors; Denervation; Disease Models, Animal; Long-Term Potentiation; Male; Memory; Memory Disorders; Mice; Olfactory Bulb; Phenylcarbamates; Rivastigmine | 2014 |
Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Cholinesterase Inhibitors; Cognitive Dysfunction; Depressive Disorder; Disease Models, Animal; Donepezil; Indans; Male; Nootropic Agents; Piperidines; Rats; Rats, Wistar; Recognition, Psychology; Rivastigmine; Stress, Psychological | 2016 |
Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Disease Models, Animal; Disks Large Homolog 4 Protein; Humans; Mice; Mice, Transgenic; Rats; Rivastigmine; Synaptosomal-Associated Protein 25 | 2016 |
Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats.
Topics: Animals; Behavior, Animal; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Ethanol; Indans; Male; Maze Learning; Memory Disorders; Motor Activity; Nootropic Agents; Piperidines; Rats, Wistar; Reaction Time; Rivastigmine; Rotarod Performance Test; Spatial Memory; Time Factors | 2016 |
Cholinergic activation affects the acute and chronic antinociceptive effects of morphine.
Topics: Acetylcholine; Analgesics, Opioid; Analysis of Variance; Animals; Area Under Curve; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Drug Synergism; Indans; Male; Mice; Morphine; Pain; Pain Measurement; Piperidines; Rivastigmine; Time Factors | 2017 |
Cholinergic Modification of Neurogenesis and Gliosis Improves the Memory of AβPPswe/PSEN1dE9 Alzheimer's Disease Model Mice Fed a High-Fat Diet.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Body Weight; Cells, Cultured; Cholinesterase Inhibitors; Conditioning, Psychological; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Gliosis; Humans; Insulin; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurogenesis; Neurons; Presenilin-1; Rivastigmine | 2017 |
Brain cholinergic impairment in liver failure.
Topics: Acetylcholine; Acetylcholinesterase; Aged; Aged, 80 and over; Animals; Behavior, Animal; Cerebral Cortex; Choline O-Acetyltransferase; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis, Experimental; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Rats; Rats, Sprague-Dawley; Rivastigmine; RNA, Messenger | 2008 |
Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.
Topics: Amnesia; Animals; Biological Transport; Brain; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Enbucrilate; Lactic Acid; Maze Learning; Mice; Nanoparticles; Neuroprotective Agents; Particle Size; Phenylcarbamates; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rivastigmine; Scopolamine | 2010 |
Acetylcholine and chronic vasculopathy in rat renal allografts.
Topics: Acetylcholine; Animals; Choline O-Acetyltransferase; Cholinesterase Inhibitors; Disease Models, Animal; Kidney; Kidney Transplantation; Leukocytes; Nerve Tissue Proteins; Phenylcarbamates; Plasma Membrane Neurotransmitter Transport Proteins; Rats; Rats, Inbred F344; Rats, Inbred Lew; Rivastigmine; Transplantation, Homologous; Vascular Diseases | 2011 |
Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.
Topics: Amyloid beta-Peptides; Analysis of Variance; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition Disorders; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Indans; Male; Mice; Mice, Inbred ICR; Motor Activity; Peptide Fragments; Phenylcarbamates; Piperidines; Recognition, Psychology; Rivastigmine | 2011 |
Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Benzopyrans; Brain; Brain-Derived Neurotrophic Factor; Catecholamines; Cholinesterase Inhibitors; Desipramine; Disease Models, Animal; Imidazoles; Immobility Response, Tonic; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phenylcarbamates; Recognition, Psychology; Rivastigmine | 2012 |
Effect of some medicinal plant extracts on the oxidative stress status in Alzheimer's disease induced in rats.
Topics: Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Neuroprotective Agents; Oxidative Stress; Phenylcarbamates; Piper nigrum; Plant Extracts; Rats; Rats, Sprague-Dawley; Rivastigmine; Salvia; Superoxide Dismutase | 2012 |
Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease.
Topics: Acetylcholinesterase; Aluminum Chloride; Aluminum Compounds; Alzheimer Disease; Analysis of Variance; Animals; Behavior, Animal; C-Reactive Protein; Chlorides; Disease Models, Animal; Gene Expression Profiling; Liposomes; Male; Maze Learning; Nanoparticles; Particle Size; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine | 2013 |
Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antibodies, Monoclonal; Basal Nucleus of Meynert; Carbamates; Cerebral Cortex; Choline O-Acetyltransferase; Cholinergic Fibers; Cholinesterase Inhibitors; Disease Models, Animal; Immunohistochemistry; Immunotoxins; Male; N-Glycosyl Hydrolases; Neural Inhibition; Neural Pathways; Neurons; Phenylcarbamates; Psychotic Disorders; Rats; Rats, Sprague-Dawley; Reflex, Startle; Ribosome Inactivating Proteins, Type 1; Rivastigmine; Saporins; Treatment Outcome | 2002 |
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Cognition; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Galantamine; Humans; Indans; Male; Memantine; Mice; Mice, Mutant Strains; Phenylcarbamates; Piperidines; Rivastigmine; Sensitivity and Specificity | 2005 |